<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029611412365</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029611412365</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Interaction Between MMP-9 Gene Polymorphisms and Smoking in Relation to Myocardial Infarction in a Uighur Population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ma</surname>
<given-names>Yi-Tong</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
<xref ref-type="corresp" rid="corresp1-1076029611412365"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Xiang</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Yi-Ning</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fu</surname>
<given-names>Zhen-Yan</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xiao-Mei</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Fen</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029611412365">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Xiang</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412365">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Bang-dang</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029611412365">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Shan</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029611412365">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Ming-Hui</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029611412365">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Xiao</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029611412365">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Bao-Zhu</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029611412365">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1076029611412365"><label>1</label>Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, PR China</aff>
<aff id="aff2-1076029611412365"><label>2</label>Xinjiang Key Laboratory of Cardiovascular Disease Research, Urumqi, PR China</aff>
<author-notes>
<corresp id="corresp1-1076029611412365">Yi-Tong Ma, Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, No 1 Liyushan Road, Urumqi 830054,PR China. Email:<email>myt-xj@163.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>1</issue>
<fpage>72</fpage>
<lpage>78</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>
<bold>Objectives:</bold> Matrix metalloproteinase 9 (MMP-9) plays a pivotal role in early atherosclerosis, vascular remodeling, and development of arterial plaque rupture. The potentially functional <italic>MMP-9</italic> gene polymorphism may contribute to the susceptibility of myocardial infarction (MI). We aimed to investigate the association between the interaction of 2 single-nucleotide polymorphisms ([SNPs] −1562C&gt;T and R279Q) of the <italic>MMP-9</italic> gene and smoking with MI in a Uighur population of China.<bold>Methods:</bold> A case–control study composed of 384 coronary angiography proven patients with MI and 451 sex-matched and ethnically matched control participants were enrolled in the study. The genotypes of the 2 selected SNPs were determined by the method of polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP).<bold>Results:</bold> Analysis of 2 SNPs, the frequency of −1562 CT and TT genotypes in MI group was significantly higher than in control group (25.52% vs 17.29%; <italic>P</italic> = .004). And the −1562 T allele showed significant association with MI (MI vs controls: 14.19% vs 9.31%; <italic>P</italic> = .002). R279Q locus did not show significant differences between patients and controls ( <italic>P</italic> &gt; .05). Multiple logistic regression analysis showed that −1562 T allele (CT or TT genotype; odds ratio [OR] 1.31, 95% confidence interval [CI] 1.22-1.40; <italic>P</italic> = .004), the interaction between −1562 T allele and smoking (OR 4.42, 95% CI 2.74-7.13; <italic>P</italic> &lt; .001), and the interaction between 279 Q allele and smoking (OR 2.07, 95% CI: 1.04-4.13; <italic>P</italic> = .021) were independent risk factors for MI.<bold>Conclusions:</bold> There findings suggest that MMP-9 −1562C&gt;T polymorphism could be associated with the susceptibility to MI. Another SNP (R279Q) polymorphism was not significantly associated with MI. The −1562C&gt;T or R279Q polymorphism of <italic>MMP-9</italic> gene and smoking have a synergistic effect and are significantly associated with the risk of MI in Chinese Uighur population, respectively.</p>
</abstract>
<kwd-group>
<kwd>matrix metalloproteinase 9</kwd>
<kwd>myocardial infarction</kwd>
<kwd>gene polymorphism</kwd>
<kwd>smoking</kwd>
</kwd-group><custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/Febraury 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1076029611412365">
<title>Introduction</title>
<p>Coronary artery disease (CAD) is a complex, chronic, and multifactorial disorder and has become a major source of morbidity and mortality in different parts of the world.<sup><xref ref-type="bibr" rid="bibr1-1076029611412365">1</xref><xref ref-type="bibr" rid="bibr2-1076029611412365"/><xref ref-type="bibr" rid="bibr3-1076029611412365"/>–<xref ref-type="bibr" rid="bibr4-1076029611412365">4</xref></sup> Myocardial infarction (MI), an extreme manifestation of CAD, usually occurs following the development of an acute occlusive thrombus due to a ruptured coronary artery atheromatous plaque. Much of the risk of MI is explained by conventional risk factors such as age, male gender, smoking, hypertension, hypercholesterolemia, diabetes mellitus, obesity, and sedentary lifestyle.<sup><xref ref-type="bibr" rid="bibr5-1076029611412365">5</xref><xref ref-type="bibr" rid="bibr6-1076029611412365"/>–<xref ref-type="bibr" rid="bibr7-1076029611412365">7</xref></sup> But the exact underlying mechanisms of MI are not fully understood, which may be due to an interaction between the individual’s genetic makeup and various environmental factors.<sup><xref ref-type="bibr" rid="bibr8-1076029611412365">8</xref>,<xref ref-type="bibr" rid="bibr9-1076029611412365">9</xref></sup> In recent years, most studies have looked at associations between polymorphic variants in candidate genes and the risk of developing MI.<sup><xref ref-type="bibr" rid="bibr10-1076029611412365">10</xref><xref ref-type="bibr" rid="bibr11-1076029611412365"/>–<xref ref-type="bibr" rid="bibr12-1076029611412365">12</xref></sup> A potential candidate gene system is the matrix metalloproteinase (MMP) family.</p>
<p>The MMPs are a large family of zinc-dependent enzymes that are capable of degrading most components of the extracellular matrix (ECM) and contribute to both normal and pathological tissue remodeling.<sup><xref ref-type="bibr" rid="bibr13-1076029611412365">13</xref></sup> Matrix metalloproteinase 9, also known as gelatinase B or 92-kDa type IV collagenase, is one of the MMPs found to be highly expressed in the vulnerable regions of atherosclerotic plaques, and for this reason it has been suggested MMP-9 plays a pivotal role in vascular remodeling and development of atherosclerotic lesion, and it also has an important role in arterial plaque rupture.<sup><xref ref-type="bibr" rid="bibr14-1076029611412365">14</xref>,<xref ref-type="bibr" rid="bibr15-1076029611412365">15</xref></sup> Epidemiological studies have shown that MMP-9 levels are increased in the circulation of patients with MI.<sup><xref ref-type="bibr" rid="bibr16-1076029611412365">16</xref>,<xref ref-type="bibr" rid="bibr17-1076029611412365">17</xref></sup> Recent research suggested that genetic variation that affects the expression of MMP-9 may contribute to the occurrence of cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr18-1076029611412365">18</xref></sup>
</p>
<p>Smoking is widely acknowledged as a major common environmental factor associated with the risk of CAD.<sup><xref ref-type="bibr" rid="bibr19-1076029611412365">19</xref>,<xref ref-type="bibr" rid="bibr20-1076029611412365">20</xref></sup> Smoking is associated with a higher serum level of cholesterol, coronary vasomotor activity, platelet aggregation, and prothombotic state.<sup><xref ref-type="bibr" rid="bibr21-1076029611412365">21</xref></sup> The smoking-associated risk of CAD has been reported to be greater in some genetic variants.<sup><xref ref-type="bibr" rid="bibr22-1076029611412365">22</xref>,<xref ref-type="bibr" rid="bibr23-1076029611412365">23</xref></sup> Knowing that in most cases MI has a multifactorial basis, involving a number of genes and environmental factors interacting to determine whether the disease will develop, we also tried to look at the association and linkage between the <italic>MMP-9</italic> gene polymorphisms and MI in a Uighur population. In addition, the interaction of the <italic>MMP-9</italic> gene polymorphisms with smoking was assessed.</p>
</sec>
<sec id="section2-1076029611412365">
<title>Materials and Methods</title>
<sec id="section3-1076029611412365">
<title>Participants</title>
<p>The study was designed as a case–control study. A total of 835 Uighur participants were recruited from January 2006 to March 2010 at the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. The case group consisted of 384 patients with an acute MI (AMI) or non-ST segment elevation myocardial infarction (NSTEMI) evidenced by coronary arteriography. Diagnosis of AMI and NSTEMI was made by characteristic symptoms (chest pain), electrocardiographic changes (new pathologic Q waves, at least 1 mm ST elevation in any 2 or more contiguous limb leads or a new left bundle branch block, or new persistent ST-T wave changes diagnostic of a non-Q wave MI), and serum creatinine kinase-MB isoenzyme (CK-MB) elevations (more than 3-fold higher than the upper reference limit) according to the guidelines.<sup><xref ref-type="bibr" rid="bibr24-1076029611412365">24</xref></sup> Those with the presence of cardiogenic shock, with known liver, thyroid, or renal diseases; malignancy or pregnancy; or with acute viral infection within the previous 4 weeks were excluded. The control group consisted of 451 participants without anomaly in coronary arteriography and no history of CAD, no symptoms suggestive of CAD, no electrocardiographic signs of CAD, no regional wall motion abnormalities, and no relevant valvular abnormalities in echocardiograms, to exclude the presence of CAD.<sup><xref ref-type="bibr" rid="bibr25-1076029611412365">25</xref></sup> Control participants with any history of heart disease, neoplasm, cardiomyopathy, or severe illness limiting life expectancy or refusing consent were excluded. Hypertension was defined as having a blood pressure above 140 mm Hg systolic and or 90 mm Hg diastolic at 3 consecutive measurements divided by 15 minutes intervals or any antihypertensive agent use.<sup><xref ref-type="bibr" rid="bibr26-1076029611412365">26</xref></sup> Hypercholesterolemia was defined as serum total cholesterol (TC) levels ≥6.2 mmol/L (240 mg/dL) or current use of antihyperlipidemic medication. Diabetes was defined as fasting plasma glucose levels ≥7.0 mmol/L (126 mg/dL) or 2 hours after 75 g of oral glucose loading glucose levels ≥11.1 mmol/L (200 mg/dL), or current use of antidiabetic medication.<sup><xref ref-type="bibr" rid="bibr27-1076029611412365">27</xref></sup> Participants were considered smokers when consuming more than 5 cigarettes per day or nonsmokers when never smoked or had stopped smoking at least 1 year before sample collection. Persons who drank 100 g or more alcohol per day in the previous 6 months were considered alcohol users. Weight and height measurements were performed with a standardized scale with light clothes and naked feet. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared.</p>
<p>Controls and patients with MI patients were matched by gender and age ± 5 years. All participants were genetically unrelated ethnic Uighur population from Xinjiang Uighur Autonomous Region of China. Each participant was interviewed after informed consent was obtained. The study was approved by the ethics committee of the First Affiliated Hospital of Xinjiang Medical University.</p>
</sec>
<sec id="section4-1076029611412365">
<title>Biochemical Analysis</title>
<p>Five milliliter venous blood samples were obtained from all participants after 12-hour fasting and placed in EDTA tubes and stored at −80°C until the time of assay. The serum concentrations of triglyceride (TG), TC, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and blood glucose were measured by the standard methods in the Central laboratory of the First Affiliated Hospital of Xinjiang Medical University.</p>
</sec>
<sec id="section5-1076029611412365">
<title>Matrix Metalloproteinase 9 Genotyping</title>
<p>Genomic DNA was extracted from peripheral blood leukocytes by standard methods (Boiteke Corporation, Beijing, China). Genotyping was performed with the method of polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). The primers of two sites were designed by the Primer Premier 5.0 software (PREMIER Biosoft International, Vancover, Canada) and syntheses were performed by the Shanghai Biological Engineering Company Limited (Shanghai, China). The PCR product of −1562C&gt;T and R279Q polymorphism sites were then digested with the restriction enzyme <italic>Sph</italic>I and <italic>Sma</italic>I (Fermentas Corporation, Lithuania) at 37°C for 16 hours and separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide. Detailed descriptions of the methods used are summarized in <xref ref-type="table" rid="table1-1076029611412365">Tables 1</xref> and <xref ref-type="table" rid="table2-1076029611412365">2</xref>.</p>
<table-wrap id="table1-1076029611412365" position="float">
<label>Table 1.</label>
<caption>
<p>PCR Primer Sets and Conditions for Matrix Metalloproteinase (MMP-
9) Gene</p>
</caption>
<graphic alternate-form-of="table1-1076029611412365" xlink:href="10.1177_1076029611412365-table1.tif"/>
<table>
<thead>
<tr>
<th align="left">Polymorphism (DbSNP No.)</th>
<th align="left">Primer Sequence (Sense/Antisense)</th>
<th align="left">Initial Denature</th>
<th align="left">Denature</th>
<th align="left">Annealing</th>
<th align="left">Extension</th>
<th align="left">Cycles</th>
<th align="left">Final Incubation</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="2">−1562C&gt;T (rs3918242)</td>
<td align="left">F:5′-GCCTGGCACATAGTAGGCCC-3′</td>
<td align="left">95°C</td>
<td align="left">94°C</td>
<td align="left">64.5°C</td>
<td align="left">72°C</td>
<td align="left">35</td>
<td align="left">72°C</td>
</tr>
<tr>
<td align="left">R:5′-CTTCCTAGCCAGCCGGCATC-3′</td>
<td align="left">5 min</td>
<td align="left">30 s</td>
<td align="left">30 s</td>
<td align="left">45 s</td>
<td align="left">
</td>
<td align="left">10 min</td>
</tr>
<tr>
<td align="left" rowspan="2">R279Q (rs17576)</td>
<td align="left">F:5′-ATGGGTCAAAGAACAGGA-3′</td>
<td align="left">95°C</td>
<td align="left">94°C</td>
<td align="left">58°C</td>
<td align="left">72°C</td>
<td align="left">30</td>
<td align="left">72°C</td>
</tr>
<tr>
<td align="left">R:5′-GGTAGACAGGGTGGAGG-3′</td>
<td align="left">5 min</td>
<td align="left">30 s</td>
<td align="left">30 s</td>
<td align="left">30 s</td>
<td align="left">
</td>
<td align="left">7 min</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-1076029611412365" position="float">
<label>Table 2.</label>
<caption>
<p>Restriction Enzymes, Conditions and Product Lengths for Analysis of MMP-9 Gene</p>
</caption>
<graphic alternate-form-of="table2-1076029611412365" xlink:href="10.1177_1076029611412365-table2.tif"/>
<table>
<thead>
<tr>
<th align="left">Polymorphism</th>
<th align="left">Restriction Enzyme</th>
<th align="left">Conditions</th>
<th align="left">Fragment Length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">−1562C&gt;T (rs3918242)</td>
<td align="left">SphI</td>
<td align="left">37°C for 16 h: PCR product 8 uL, 10× buffer 2 uL,</td>
<td align="left">CC 435/435 bp</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left">H<sub>2</sub>O<sub>2</sub> 10 uL, SphI 2U CT 435/188 247 bp</td>
</tr>
<tr>
<td/>
<td/>
<td align="left">
</td>
<td align="left">TT 188 247/188 247 bp</td>
</tr>
<tr>
<td align="left">R279Q (rs17576)</td>
<td align="left">SmaI</td>
<td align="left">37°C for 16 h: PCR product 8 uL, 10× buffer 2 uL,</td>
<td align="left">GG 96 181/96 181 bp</td>
</tr>
<tr>
<td/>
<td/>
<td align="left">H<sub>2</sub>O<sub>2</sub> 10 uL, SmaI 2U</td>
<td align="left">GA 96 181 bp/277 bp</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left">AA 277/277 bp</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029611412365">
<p>Abbreviations: MMP-9, matrix metalloproteinase; PCR, polymerase chain reaction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-1076029611412365">
<title>Statistical Analysis</title>
<p>All data were analyzed using SPSS for Windows 13.0 (SPSS Inc, Chicago, Illinois). All polymorphisms were tested for confirmation with Hardy-Weinberg expectations in both groups separately. Measurement data are shown as means ± standard deviation (SD), and the differences between the case and control groups were evaluated using the chi-square test (for categorical variables) and independent sample <italic>t</italic> test (for continuous variables). Differences in the frequencies of the alleles and genotypes were compared between patient and control groups by the chi-square test when appropriate. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) for the effect of MMP-9 polymorphisms on MI risk using logistic regression analyses adjusted for the effects of other cardiovascular risk factors. Logistic regression analysis was also used to test for interaction between MMP-9 polymorphisms and smoking. A 2-tailed <italic>P</italic> &lt; .05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section7-1076029611412365">
<title>Results</title>
<sec id="section8-1076029611412365">
<title>Clinical Characteristics</title>
<p>The distributions of clinical characteristics between MI group and control group are shown in <xref ref-type="table" rid="table3-1076029611412365">Table 3</xref>. No significant differences were seen between the 2 groups with regard to gender distribution, age, triglyceride, HDL-C, apolipoprotein A I, apolipoprotein B, blood urea nitrogen, serum creatinine, and the drinking status (all <italic>P</italic> &gt; .05). However, TC, LDL-Co, systolic blood pressure, diastolic blood pressure, and BMI were significantly higher in the case group than in the control group (all <italic>P</italic> &lt; .05). There were significantly higher percentages of smokers and patients with diabetes mellitus or hypertension in the case group (all <italic>P</italic> &lt; .05).</p>
<table-wrap id="table3-1076029611412365" position="float">
<label>Table 3.</label>
<caption>
<p>Clinical Characteristics of the Study Population</p>
</caption>
<graphic alternate-form-of="table3-1076029611412365" xlink:href="10.1177_1076029611412365-table3.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Variable</th>
<th align="center">MI group</th>
<th align="center">Control group</th>
<th align="center" rowspan="2"><italic>P</italic> Value</th>
</tr>
<tr>
<th align="center">(n = 384)</th>
<th align="center">(n = 451)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female, %)</td>
<td>129 (33.6)</td>
<td>160 (35.5)</td>
<td>.569</td>
</tr>
<tr>
<td>Age (years)</td>
<td>55.6 ± 10.9</td>
<td>54.1 ± 10.3</td>
<td>.116</td>
</tr>
<tr>
<td>Smoking (n, %)</td>
<td>175 (45.6)</td>
<td>140 (31.0)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Drinking (n, %)</td>
<td>131 (34.1)</td>
<td>166 (36.8)</td>
<td>.418</td>
</tr>
<tr>
<td>Hypertension (n, %)</td>
<td>244 (63.5)</td>
<td>143 (31.7)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Diabetes mellitus (n, %)</td>
<td>164 (42.7)</td>
<td>78 (17.3)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>SBP (mm Hg)<sup><xref ref-type="table-fn" rid="table-fn3-1076029611412365">a</xref></sup>
</td>
<td>136.2 ± 20.9</td>
<td>121.4 ± 16.2</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>DBP (mm Hg)<sup><xref ref-type="table-fn" rid="table-fn3-1076029611412365">a</xref></sup>
</td>
<td>86.3 ± 12.3</td>
<td>77.5 ± 10.8</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>4.42 ± 1.14</td>
<td>4.17 ± 1.01</td>
<td>.011</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.97 ± 1.10</td>
<td>1.94 ± 1.26</td>
<td>.754</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>2.65 ± 0.91</td>
<td>2.45 ± 0.86</td>
<td>.017</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.13 ± 0.53</td>
<td>1.04 ± 0.61</td>
<td>.1</td>
</tr>
<tr>
<td>ApoA I(mmol/L)</td>
<td>1.19 ± 0.23</td>
<td>1.15 ± 0.23</td>
<td>.081</td>
</tr>
<tr>
<td>ApoB (mmol/L)</td>
<td>0.95 ± 0.53</td>
<td>0.92 ± 0.71</td>
<td>.531</td>
</tr>
<tr>
<td>BNU (mmol/L)</td>
<td>5.18 ± 1.85</td>
<td>4.95 ± 1.52</td>
<td>.127</td>
</tr>
<tr>
<td>SCr (umol/L)</td>
<td>79.70 ± 20.01</td>
<td>75.98 ± 21.27</td>
<td>.05</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>27.10 ± 3.62</td>
<td>24.99 ± 4.17</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1076029611412365">
<p>Abbreviation: SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ApoA I, apolipoprotein A I; Apo B, apolipoprotein B; BUN, blood urea nitrogen; SCr, serum creatinine; BMI, body mass index; MI, myocardial infarction.</p>
</fn>
<fn id="table-fn3-1076029611412365">
<p>
<sup>a</sup>1 mm Hg = 0.133 Kpa</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-1076029611412365">
<title>Matrix Metalloproteinase 9 − 1562 C&gt;T and R 279 Q Genotype and Allele Frequency Distribution</title>
<p>Genotype and allele frequencies of MMP-9 (−1562C&gt;T and R279Q) in controls and patients with MI are shown in <xref ref-type="table" rid="table4-1076029611412365">Table 4</xref>. The distribution of genotypes were not significantly deviated from the Hardy-Weinberg equilibrium in both MI and control groups (all <italic>P</italic> &gt; .05). The distribution of −1562C&gt;T genotype was significantly different between the MI and control group ( <italic>χ</italic>
<sup>2</sup> = 9.054, <italic>P</italic> = .011), and the −1562 T allele frequency was significantly higher in MI group than that in the control group (14.19% vs 9.31%; <italic>P</italic> = .002). The frequency of variant genotypes (CT/TT) for −1562C&gt;T in the patients with MI (25.52%) was significantly higher than that in the controls (17.29%; <italic>P</italic> = .004). By further analyses we found that an individual who had T allele (TT or CT genotype) was at an increased crude risk of MI (OR = 1.64, <italic>P</italic> = .004). There were no significant differences in both genotypes and allele distribution of the R279Q polymorphism between 2 groups (all <italic>P</italic> &gt; .05).</p>
<table-wrap id="table4-1076029611412365" position="float">
<label>Table 4.</label>
<caption>
<p>Genotype Distribution and Allele Frequencies of MMP-9 Polymorphisms Between 2 Groups</p>
</caption>
<graphic alternate-form-of="table4-1076029611412365" xlink:href="10.1177_1076029611412365-table4.tif"/>
<table>
<thead>
<tr>
<th>Polymorphism</th>
<th>MI group, N = 384 (%)</th>
<th>Control group, N = 451 (%)</th>
<th>Crude OR (95% CI)</th>
<th><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">−1562C&gt;T</td>
</tr>
<tr>
<td> CC</td>
<td>286 (74.48)</td>
<td>373 (82.71)</td>
<td>1 (reference)</td>
<td>
</td>
</tr>
<tr>
<td> CT</td>
<td>87 (22.66)</td>
<td>72 (15.96)</td>
<td>1.58 (1.11-2.23)</td>
<td>.01</td>
</tr>
<tr>
<td> TT</td>
<td>11 (2.86)</td>
<td>6 (1.33)</td>
<td>2.39 (0.87-6.54)</td>
<td>.081</td>
</tr>
<tr>
<td> CT+TT</td>
<td>98 (25.52)</td>
<td>78 (17.29)</td>
<td>1.64 (1.17-2.29)</td>
<td>.004</td>
</tr>
<tr>
<td> C allele</td>
<td>659 (85.81)</td>
<td>818 (90.69)</td>
<td>1 (reference)</td>
<td>
</td>
</tr>
<tr>
<td> T allele</td>
<td>109 (14.19)</td>
<td>84 (9.31)</td>
<td>1.61 (1.2-2.2)</td>
<td>.002</td>
</tr>
<tr>
<td colspan="5">R279Q</td>
</tr>
<tr>
<td> RR</td>
<td>185 (48.18)</td>
<td>239 (52.99)</td>
<td>1 (reference)</td>
<td>
</td>
</tr>
<tr>
<td> RQ</td>
<td>150 (39.06)</td>
<td>167 (37.03)</td>
<td>1.16 (0.87-1.55)</td>
<td>.318</td>
</tr>
<tr>
<td> QQ</td>
<td>49 (12.76)</td>
<td>45 (9.98)</td>
<td>1.407 (0.90-2.2)</td>
<td>.134</td>
</tr>
<tr>
<td> RQ+QQ</td>
<td>199 (51.82)</td>
<td>212 (47.01)</td>
<td>1.213 (0.92-1.60)</td>
<td>.165</td>
</tr>
<tr>
<td> R allele</td>
<td>520 (67.71)</td>
<td>645 (71.51)</td>
<td>1 (reference)</td>
<td>
</td>
</tr>
<tr>
<td> Q allele</td>
<td>248 (32.29)</td>
<td>257 (28.49)</td>
<td>1.197 (0.97-1.41)</td>
<td>.092</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1076029611412365">
<p>Abbreviation: MMP, matrix metalloproteinase; CC, homozygous C allele of <italic>MMP-9</italic> gene −1562C&gt;T; CT, heterozygous allele of MMP-9 gene −1562C&gt;T; TT, homozygous T allele of <italic>MMP-9</italic> gene −1562C&gt;T; RR, homozygous R allele of <italic>MMP-9</italic> gene R279Q; RQ, heterozygous allele of <italic>MMP-9</italic> gene R279Q; QQ, homozygous Q allele of <italic>MMP-9</italic> gene R279Q; MI, myocardial infarction; OR, odds ratio.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-1076029611412365">
<title>Interaction Between Smoking and MMP-9 Polymorphisms for MI</title>
<p>The whole sample was further divided according to the current smoking status, and the differences by −1562C&gt;T or R279Q polymorphisms (homozygous or heterozygous carriers) were evaluated. At −1562C&gt;T locus, compared with the CC genotype and nonsmokers, smokers carrying mutant T allele (CT or TT genotype) showed significantly higher risk (OR = 3.64, 95% CI: 2.04-6.49). Among individual who carry CC genotype, smoking history had 1.8-fold risk of MI (OR = 1.81, 95% CI: 1.32-2.49). In participants who did not smoke, the −1562 T allele (CT or TT genotype) was associated with an increase risk of MI (OR = 1.56, 95% CI: 1.03-2.37). At R279Q polymorphism locus, compared with 279 RR genotype carriers who did not smoke, the smoker with 279 RQ or QQ genotype had high risk of MI (OR = 2.44, 95% CI: 1.62-3.69). Among individual who had RR genotype, smoking history was associated with a 1.56-fold risk of MI (OR = 1.56, 95% CI: 1.05-2.31; <xref ref-type="table" rid="table5-1076029611412365">Table 5</xref>).</p>
<table-wrap id="table5-1076029611412365" position="float">
<label>Table 5.</label>
<caption>
<p>Association Between Smoking and the MMP-9 Gene Polymorphisms on MI <sup><xref ref-type="table-fn" rid="table-fn6-1076029611412365">a</xref></sup></p></caption>
<graphic alternate-form-of="table5-1076029611412365" xlink:href="10.1177_1076029611412365-table5.tif"/>
<table>
<thead>
<tr>
<th>Genotype</th>
<th>Smoking</th>
<th>MI</th>
<th>Controls</th>
<th>Crude OR (95% CI)</th>
<th><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">MMP-9 −1562C&gt;T</td>
</tr>
<tr>
<td> CC</td>
<td>No</td>
<td>153</td>
<td>252</td>
<td>1 (reference)</td>
<td>
</td>
</tr>
<tr>
<td> CT/TT</td>
<td>No</td>
<td>56</td>
<td>59</td>
<td>1.56 (1.03-2.37)</td>
<td>0.03</td>
</tr>
<tr>
<td> CC</td>
<td>Yes</td>
<td>133</td>
<td>121</td>
<td>1.81 (1.32-2.49)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> CT/TT</td>
<td>Yes</td>
<td>42</td>
<td>19</td>
<td>3.64 (2.04-6.49)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td colspan="6">MMP-9 R279Q</td>
</tr>
<tr>
<td> RR</td>
<td>No</td>
<td>102</td>
<td>157</td>
<td>1 (reference)</td>
<td>
</td>
</tr>
<tr>
<td> RQ/QQ</td>
<td>No</td>
<td>107</td>
<td>154</td>
<td>1.07 (0.75-1.52)</td>
<td>0.71</td>
</tr>
<tr>
<td> RR</td>
<td>Yes</td>
<td>83</td>
<td>82</td>
<td>1.56 (1.05-2.31)</td>
<td>0.03</td>
</tr>
<tr>
<td> RQ/QQ</td>
<td>Yes</td>
<td>92</td>
<td>58</td>
<td>2.44 (1.62-3.69)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1076029611412365">
<p>Abbreviation: MMP, matrix metalloproteinase; CC, homozygous C allele of <italic>MMP-9</italic> gene −1562C&gt;T; CT, heterozygous allele of <italic>MMP-9</italic> gene −1562C&gt;T; TT, homozygous T allele of <italic>MMP-9</italic> gene −1562C&gt;T; MI, myocardial infarction; CI, confidence interval; OR, odds ratio.</p>
</fn>
<fn id="table-fn6-1076029611412365">
<p>
<sup>a</sup> Dates are presented as number of patients.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-1076029611412365">
<title>Identification of Independent Risk Factors for MI</title>
<p>A multiple logistic regression model showed 3 independent factors: diabetes mellitus (OR = 2.94, 95% CI: 1.46-5.91; <italic>P</italic> &lt; .001), hypertension (OR = 2.51, 95% CI: 1.59-3.97; <italic>P</italic> &lt; .001), and smoking (OR = 1.89, 95% CI: 1.52-2.34; <italic>P</italic> = .004). After adjusting for those conventional cardiovascular risk factors such as age, gender, hypertension, hypercholesterolemia, and diabetes mellitus, the −1562 T allele (TT or CT genotype) carriers still had an approximately 1.3-fold higher relative risk of developing MI than those with the CC homozygote (OR = 1.31, 95% CI: 1.22-1.40; <italic>P</italic> = .004). Moreover, there was a synergistic effect between smoking and −1562 T allele for the occurrence of MI (OR = 4.42, 95% CI: 2.74-7.13; <italic>P</italic> &lt; .001). In addition, we found no association between R279Q polymorphism and MI risk in this cohort. But the interaction of R279Q polymorphism with smoking was an independent risk factor for MI (OR = 2.07, 95% CI: 1.04-4.13; <italic>P</italic> = .021), it was high than the independent effect of smoking (OR = 1.89) to MI (<xref ref-type="table" rid="table6-1076029611412365">Table 6</xref>).</p>
<table-wrap id="table6-1076029611412365" position="float">
<label>Table 6.</label>
<caption>
<p>Logistic Regression Analysis of Association Between the MMP-9 Genotypes and Risk of MI</p>
</caption>
<graphic alternate-form-of="table6-1076029611412365" xlink:href="10.1177_1076029611412365-table6.tif"/>
<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>B</th>
<th>SE</th>
<th>Wald χ<sup>2</sup>
</th>
<th>
<italic>P</italic>
</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM</td>
<td>1.077</td>
<td>0.357</td>
<td>14.176</td>
<td>0</td>
<td>2.94</td>
<td>1.46-5.91</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.92</td>
<td>0.233</td>
<td>15.579</td>
<td>0</td>
<td>2.51</td>
<td>1.59-3.97</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.635</td>
<td>0.111</td>
<td>8.081</td>
<td>.004</td>
<td>1.89</td>
<td>1.52-2.34</td>
</tr>
<tr>
<td>−1562 T allele</td>
<td>0.268</td>
<td>0.037</td>
<td>5.644</td>
<td>.018</td>
<td>1.31</td>
<td>1.22-1.40</td>
</tr>
<tr>
<td>−1562C&gt;T and smoking<sup><xref ref-type="table-fn" rid="table-fn8-1076029611412365">a</xref></sup>
</td>
<td>1.468</td>
<td>0.244</td>
<td>16.927</td>
<td>0</td>
<td>4.42</td>
<td>2.74-7.13</td>
</tr>
<tr>
<td>R279Q and smoking<sup><xref ref-type="table-fn" rid="table-fn9-1076029611412365">b</xref></sup>
</td>
<td>0.727</td>
<td>0.352</td>
<td>5.347</td>
<td>0.021</td>
<td>2.07</td>
<td>1.04-4.13</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1076029611412365">
<p>Abbreviation: MMP, matrix metalloproteinase; SE, standard error; MI, myocardial infarction; CI, confidence interval; OR, odds ratio; DM, diabetes mellitus.</p>
</fn>
<fn id="table-fn8-1076029611412365">
<p>
<sup>a</sup> The interaction between smoking and MMP-9 −1562 T allele.</p>
</fn>
<fn id="table-fn9-1076029611412365">
<p>
<sup>b</sup> The interaction between smoking and MMP-9 279 Q allele.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-1076029611412365">
<title>Discussion</title>
<p>To the best of our knowledge, this is the first study that has investigated the gene–environment interaction between smoking and 2 potentially functional polymorphisms of the <italic>MMP-9</italic> gene in relation to MI susceptibility in Chinese Uighur population. Our data demonstrated that the −1562 T allele of <italic>MMP-9</italic> gene is significantly associated with an increased risk of MI. However, we found no association between R279Q polymorphism and MI risk in this cohort. In addition, there was significant synergism between 2 locus polymorphisms and smoking to MI in this population.</p>
<p>The human <italic>MMP-9</italic> gene is located on chromosome 20q12.2-13.1, and a number of SNPs in the promoter, coding, and untranslated regions have been reported.<sup><xref ref-type="bibr" rid="bibr28-1076029611412365">28</xref></sup> Of these, 2 polymorphisms are of special interest: promoter −1562C&gt;T polymorphism and codon 279 polymorphism (R279Q). In the former polymorphism, functional studies indicate that the −1562C&gt;T polymorphism has an allele-specific effect on MMP-9 transcription. DNA-protein interaction assays have revealed that the sequence between nucleotide position −1567 and −1559 relative to the transcription start site of the <italic>MMP-9</italic> gene, which encompasses the −1562 polymorphic site, can interact with a nuclear protein whose entity is still unknown.<sup><xref ref-type="bibr" rid="bibr29-1076029611412365">29</xref></sup> And the latter is located in the gelatinase-specific fibronectin type II domain, which leads to an amino acid exchange (arginine [R] to glutamine [Q]) in the catalytic domain which presumably enhances substrate binding.<sup><xref ref-type="bibr" rid="bibr30-1076029611412365">30</xref>,<xref ref-type="bibr" rid="bibr31-1076029611412365">31</xref></sup> It is therefore possible that the amino acid conversion associated with this polymorphism affects the activity of this enzyme.</p>
<p>Since Zhang et al<sup><xref ref-type="bibr" rid="bibr29-1076029611412365">29</xref></sup> reported that the −1562 T allele of MMP-9 had a higher promoter activity and T allele carriers tended to have a higher risk of severe CAD, other studies have also confirmed this association with CAD.<sup><xref ref-type="bibr" rid="bibr32-1076029611412365">32</xref>,<xref ref-type="bibr" rid="bibr33-1076029611412365">33</xref></sup> But the results were still not consistent, because 3 published studies on 3266 German and 268 Turks with angiographically documented CAD failed to confirm an association with the T allele.<sup><xref ref-type="bibr" rid="bibr34-1076029611412365">34</xref>,<xref ref-type="bibr" rid="bibr35-1076029611412365">35</xref></sup> Recently, Zhi et al<sup><xref ref-type="bibr" rid="bibr36-1076029611412365">36</xref></sup> found that MMP-9 −1562 CT/TT genotypes may contribute to CAD in diabetics and MI in CAD patients in a Chinese population. Fallah et al<sup><xref ref-type="bibr" rid="bibr37-1076029611412365">37</xref></sup> reported that the −1562C&gt;T polymorphism in the <italic>MMP-9</italic> gene potentially play a role in the manifestation of coronary atherosclerosis but did not have any effect on the number of diseased vessels in Iranians. Genetic polymorphisms may vary among different ethnic groups. In this study, we found that −1562 CT/TT genotypes were associated with a significantly increased risk of MI. This is consistent with the studies from evidence that genetic epidemiology indicates that −1562 T allele carriers are predisposed to the development of coronary atherosclerosis that results in significant coronary stenosis.<sup><xref ref-type="bibr" rid="bibr32-1076029611412365">32</xref></sup> At R279Q locus, in 1 study,<sup><xref ref-type="bibr" rid="bibr38-1076029611412365">38</xref></sup> the 279Q allele was associated with increased MMP-9 levels and the combined end point of cardiovascular death and nonfatal MI. Whereas in the other 3 studies, R279Q polymorphism was not found to be associated with the risk of CAD and stable angina.<sup><xref ref-type="bibr" rid="bibr32-1076029611412365">32</xref>,<xref ref-type="bibr" rid="bibr39-1076029611412365">39</xref>,<xref ref-type="bibr" rid="bibr40-1076029611412365">40</xref></sup> Similar to the findings of the above-mentioned 3 studies, we did not find significant main effects of R279Q on MI risk.</p>
<p>Smoking doubles the risk of MI and ischemic stroke,<sup><xref ref-type="bibr" rid="bibr41-1076029611412365">41</xref></sup> but the mechanisms by which smoking increases the risk of these atherothrombotic events are not fully understood. Studies indicated that smoking enhances systemic coagulability, as evidenced by increased circulating thrombin generation and activity,<sup><xref ref-type="bibr" rid="bibr42-1076029611412365">42</xref></sup> fibrinogen levels,<sup><xref ref-type="bibr" rid="bibr42-1076029611412365">42</xref>,<xref ref-type="bibr" rid="bibr43-1076029611412365">43</xref></sup> platelet activation,<sup><xref ref-type="bibr" rid="bibr43-1076029611412365">43</xref></sup> and enhanced plaque tissue factor content and procoagulant activity,<sup><xref ref-type="bibr" rid="bibr44-1076029611412365">44</xref></sup> by which smoking may predispose to acute arterial thrombosis.</p>
<p>It has been reported that MMP-9 brings about de-stabilizing structural changes in vulnerable atherosclerotic plaques.<sup><xref ref-type="bibr" rid="bibr14-1076029611412365">14</xref>,<xref ref-type="bibr" rid="bibr45-1076029611412365">45</xref></sup> Matrix metalloproteinase 9 also potentiates the chemokine interleukin (IL)-8 and modifies the local chemokine profile,<sup><xref ref-type="bibr" rid="bibr46-1076029611412365">46</xref></sup> and hence may promote cellular infiltration of the plaque, weakening the fiber cap of the atherosclerotic plaque, and increasing the size of the lipid core.<sup><xref ref-type="bibr" rid="bibr47-1076029611412365">47</xref>,<xref ref-type="bibr" rid="bibr48-1076029611412365">48</xref></sup> These processes render the plaque susceptible to rupture due to reduced mechanical strength and hence increase the probability of atherothrombotic ischemia. As we know, thrombosis is generally accepted as the most common pathogenetic pathway of MI. Thus, we speculated that there should be a synergistic interaction between the effect of smoking and the MMP-9 genetic variation for MI.</p>
<p>In our study population, compared with the nonsmoker with −1562 CC genotype, the smoker with −1562 CT or TT genotype was associated with a 1.31-fold risk of MI. Multiple logistic regression analysis showed that the interaction between smoking and −1562 T allele significantly increase a 4.42-fold risk of MI. Although R279Q locus did not show significant differences between patients and controls, but the smoker with 279Q allele (RQ or QQ genotype) was significant risk factor for MI (OR = 2.07, 95% CI: 1.04-4.13; <italic>P</italic> = .001). The interaction between R279Q polymorphism and smoking was high than the independent effect of smoking (OR = 1.89). However, our relatively small study may influence the results. Thus, the results need to be replicated in other populations from different parts of China, and further investigations should be performed to explore the mechanisms of this gene–environment or other possible pharmacokinetic interactions.</p>
<sec id="section13-1076029611412365">
<title>Limitations of This Study</title>
<p>There are some limitations in the present study, the most obvious limitation of the present study is its sample size, though it had enough power to detect a moderate level of ORs, but it may have led to weak statistical significance and wide CIs when estimating ORs. In addition, the sample was well characterized and was from a homogenous Uighur population, which reduces the risks of population stratification and false associations.</p>
</sec>
</sec>
<sec id="section14-1076029611412365">
<title>Conclusions</title>
<p>This study suggested that MMP-9 −1562C&gt;T polymorphism could be associated with the susceptibility to MI in Chinese Uighur population, and the −1562 T allele carriers might be at high risk of the development of MI. The interaction between −1562C&gt;T polymorphism and smoking was a significantly independent risk factor for MI. The R279Q polymorphism was not associated with MI, but the interaction between it and smoking had significantly increased risk of MI.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1076029611412365">
<p>The authors declared no conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1076029611412365">
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by the Great Technology Special Item Foundation of Xinjiang, China (200733146-3).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029611412365">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tobin</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Braund</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Burton</surname>
<given-names>PR</given-names>
</name>
<etal/>
</person-group>. <article-title>Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study</article-title>. <source>Eur Heart J</source>. <year>2004</year>;<volume>25</volume>(<issue>6</issue>):<fpage>459</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr2-1076029611412365">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samani</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Erdmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>AS</given-names>
</name>
<etal/>
</person-group>. <article-title>Genomewide association analysis of coronary artery disease</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>5</issue>):<fpage>443</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr3-1076029611412365">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashavaid</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Shalia</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Kondkar</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Todur</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>SR.</given-names>
</name>
</person-group> <article-title>Gene polymorphism and coronary risk factors in Indian populations</article-title>. <source>Clin Chem Lab Med</source>. <year>2002</year>;<volume>40</volume>(<issue>10</issue>):<fpage>975</fpage>–<lpage>985</lpage>.</citation>
</ref>
<ref id="bibr4-1076029611412365">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirashiki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Murase</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of gene polymorphisms with coronary artery disease in low or high risk subjects defined by conventional risk factors</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>42</volume>(<issue>8</issue>):<fpage>1429</fpage>–<lpage>1437</lpage>.</citation>
</ref>
<ref id="bibr5-1076029611412365">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Odell</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kannel</surname>
<given-names>WB.</given-names>
</name>
</person-group> <article-title>An updated coronary risk profile. A statement for health professionals</article-title>. <source>Circulation</source>. <year>1991</year>;<volume>83</volume>(<issue>1</issue>):<fpage>356</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr6-1076029611412365">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kannel</surname>
<given-names>WB.</given-names>
</name>
</person-group> <article-title>Lipids, diabetes, and coronary heart disease: insights from the Framingham study</article-title>. <source>Am Heart J</source>. <year>1985</year>;<volume>110</volume>(<issue>5</issue>):<fpage>1100</fpage>–<lpage>1107</lpage>.</citation>
</ref>
<ref id="bibr7-1076029611412365">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yano</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>McGee</surname>
<given-names>DL.</given-names>
</name>
</person-group> <article-title>Ten-year incidence of coronary heart disease in the honolulu heart program. relationship to biologic and lifestyle characteristics</article-title>. <source>Am J Epidemiol</source>. <year>1984</year>;<volume>119</volume>(<issue>5</issue>):<fpage>653</fpage>–<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr8-1076029611412365">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hlatky</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Quertermous</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Boothroyd</surname>
<given-names>DB</given-names>
</name>
<etal/>
</person-group>. <article-title>Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease</article-title>. <source>Am Heart J</source>. <year>2007</year>;<volume>154</volume>(<issue>6</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr9-1076029611412365">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marenberg</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Risch</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Berkman</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Floderus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>de Faire</surname>
<given-names>U.</given-names>
</name>
</person-group> <article-title>Genetic susceptibility to death from coronary heart disease in a study of twins</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>330</volume>(<issue>15</issue>):<fpage>1041</fpage>–<lpage>1046</lpage>.</citation>
</ref>
<ref id="bibr10-1076029611412365">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kallel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sediri</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sbai</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>The paraoxonase L55M and Q192R gene polymorphisms and myocardial infarction in a Tunisian population</article-title>. <source>Clin Biochem</source>. <year>2010</year>;<volume>43</volume>(<issue>18</issue>):<fpage>1461</fpage>–<lpage>1463</lpage>.</citation>
</ref>
<ref id="bibr11-1076029611412365">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaderian</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Akbarzadeh Najar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tabatabaei Panah</surname>
<given-names>AS.</given-names>
</name>
</person-group> <article-title>Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction</article-title>. <source>Coron Artery Dis</source>. <year>2010</year>;<volume>21</volume>(<issue>6</issue>):<fpage>330</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr12-1076029611412365">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujimaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yokoi</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of genetic variants in SEMA3F, CLEC16A, LAMA3, and PCSK2 with myocardial infarction in Japanese individuals</article-title>. <source>Atherosclerosis</source>. <year>2010</year>;<volume>210</volume>(<issue>2</issue>):<fpage>468</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr13-1076029611412365">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spinale</surname>
<given-names>FG.</given-names>
</name>
</person-group> <article-title>Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function</article-title>. <source>Physiol Rev</source>. <year>2007</year>;<volume>87</volume>(<issue>4</issue>):<fpage>1285</fpage>–<lpage>1342</lpage>.</citation>
</ref>
<ref id="bibr14-1076029611412365">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galis</surname>
<given-names>ZS</given-names>
</name>
<name>
<surname>Khatri</surname>
<given-names>JJ.</given-names>
</name>
</person-group> <article-title>Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly</article-title>. <source>Circ Res</source>. <year>2002</year>;<volume>90</volume>(<issue>3</issue>):<fpage>251</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr15-1076029611412365">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loftus</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Naylor</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Goodall</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased matrix metalloproteinase-9 activity in unstable carotid plaques: A potential role in acute plaque disruption</article-title>. <source>Stroke</source>. <year>2000</year>;<volume>31</volume>(<issue>1</issue>):<fpage>40</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr16-1076029611412365">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blankenberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rupprecht</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>12</issue>):<fpage>1579</fpage>–<lpage>1585</lpage>.</citation>
</ref>
<ref id="bibr17-1076029611412365">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>SQ</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction</article-title>. <source>Eur Heart J</source>. <year>2008</year>;<volume>29</volume>(<issue>17</issue>):<fpage>2116</fpage>–<lpage>2124</lpage>.</citation>
</ref>
<ref id="bibr18-1076029611412365">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henney</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression</article-title>. <source>Ann N Y Acad Sci</source>. <year>2000</year>;<volume>902</volume>:<fpage>27</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr19-1076029611412365">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tosteson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>The primary prevention of myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>326</volume>(<issue>21</issue>):<fpage>1406</fpage>–<lpage>1416</lpage>.</citation>
</ref>
<ref id="bibr20-1076029611412365">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilhelmsson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vedin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Elmfeldt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tibblin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wilhelmsen</surname>
<given-names>L.</given-names>
</name>
</person-group> <article-title>Smoking and myocardial infarction</article-title>. <source>Lancet</source>. <year>1975</year>;<volume>l</volume>(<issue>7904</issue>):<fpage>415</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr21-1076029611412365">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazzano</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muntner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vupputuri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Whelton</surname>
<given-names>PK.</given-names>
</name>
</person-group> <article-title>Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States</article-title>. <source>Ann Intern</source>. <year>Med. 2003</year>;<volume>138</volume>(<issue>11</issue>):<fpage>891</fpage>–<lpage>897</lpage>.</citation>
</ref>
<ref id="bibr22-1076029611412365">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>YT</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2010</year>;<volume>16</volume>(<issue>5</issue>):<fpage>579</fpage>–<lpage>583</lpage>.</citation>
</ref>
<ref id="bibr23-1076029611412365">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>YN</given-names>
</name>
<etal/>
</person-group>. <article-title>Interaction between COX-2 G-765C and smoking in relation to coronary artery disease in a Chinese Uighur population</article-title>. <source>Clin Chem Lab Med</source>. <year>2010</year>;<volume>49</volume>(<issue>1</issue>):<fpage>166</fpage>–<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr24-1076029611412365">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alpert</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Thygesen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Antman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bassand</surname>
<given-names>JP.</given-names>
</name>
</person-group> <article-title>Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2000</year>;<volume>36</volume>(<issue>3</issue>):<fpage>959</fpage>–<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr25-1076029611412365">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz-Narvaez</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kirchdorfer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>H.</given-names>
</name>
</person-group> <article-title>ApoC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica</article-title>. <source>J Lipid Res</source>. <year>2005</year>;<volume>46</volume>(<issue>12</issue>):<fpage>2605</fpage>–<lpage>2613</lpage>.</citation>
</ref>
<ref id="bibr26-1076029611412365">
<label>26</label>
<citation citation-type="journal">
<collab collab-type="author">1999 world health organization-international society of hypertension guidelines for the management of hypertension</collab>. <article-title>Guidelines subcommittee</article-title>. <source>J hypertens</source>. <year>1999</year>;<volume>17</volume>(<issue>2</issue>):<fpage>151</fpage>–<lpage>183</lpage>.
</citation>
</ref>
<ref id="bibr27-1076029611412365">
<label>27</label>
<citation citation-type="journal">
<collab collab-type="author">World health organization study group</collab>. <article-title>Diabetes mellitus</article-title>. <source>WHO Tech Rep Ser</source>. <year>1985</year>;<volume>727</volume>:<fpage>1</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr28-1076029611412365">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Henney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hamsten</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1</article-title>. <source>Hum Genet</source>. <year>1999</year>;<volume>105</volume>(<issue>5</issue>):<fpage>418</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr29-1076029611412365">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>99</volume>(<issue>14</issue>):<fpage>1788</fpage>–<lpage>1794</lpage>.</citation>
</ref>
<ref id="bibr30-1076029611412365">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allan</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Docherty</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Huskisson</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>G.</given-names>
</name>
</person-group> <article-title>Binding of gelatinases A and B to type-I collagen and other matrix components</article-title>. <source>Biochem J</source>. <year>1998</year>;<volume>309</volume>(<issue>pt 1</issue>):<fpage>299</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr31-1076029611412365">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Farrell</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Pourmotabbed</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B</article-title>. <source>J Biol Chem</source>. <year>2000</year>;<volume>275</volume>(<issue>36</issue>):<fpage>27964</fpage>–<lpage>27972</lpage>.</citation>
</ref>
<ref id="bibr32-1076029611412365">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tapper</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease</article-title>. <source>J Mol Med</source>. <year>2003</year>;<volume>81</volume>(<issue>5</issue>):<fpage>321</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr33-1076029611412365">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Chae</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>KW</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention</article-title>. <source>J Hum Genet</source>. <year>2002</year>;<volume>47</volume>(<issue>2</issue>):<fpage>88</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr34-1076029611412365">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haberbosch</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gardemann</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Gelatinase B C(−1562)T polymorphism in relation to ischaemic heart disease</article-title>. <source>Scand J Clin Lab Invest</source>. <year>2005</year>;<volume>65</volume>(<issue>6</issue>):<fpage>513</fpage>–<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr35-1076029611412365">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alp</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Menevse</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tulmac</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population</article-title>. <source>DNA Cell Biol</source>. <year>2009</year>;<volume>28</volume>(<issue>7</issue>):<fpage>343</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr36-1076029611412365">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population</article-title>. <source>Mol Biol Rep</source>. <year>2010</year>;<volume>37</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr37-1076029611412365">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fallah</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seifi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ghasemi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Firoozrai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Samadikuchaksaraei</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects</article-title>. <source>J Clin lab Anal</source>. <year>2010</year>;<volume>24</volume>(<issue>5</issue>):<fpage>305</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr38-1076029611412365">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blankenberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rupprecht</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>12</issue>):<fpage>1579</fpage>–<lpage>1585</lpage>.</citation>
</ref>
<ref id="bibr39-1076029611412365">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina</article-title>. <source>Yonsei Med J</source>. <year>2002</year>;<volume>43</volume>(<issue>4</issue>):<fpage>473</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr40-1076029611412365">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamblin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bauters</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hermant</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lablanche</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Helbecque</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Amouyel</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>40</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr41-1076029611412365">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ockene</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>NH.</given-names>
</name>
</person-group> <article-title>Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>96</volume>(<issue>9</issue>):<fpage>3243</fpage>–<lpage>3247</lpage>.</citation>
</ref>
<ref id="bibr42-1076029611412365">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benowitz</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
</person-group> <article-title>Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking</article-title>. <source>J Am Coll Cardiol</source>. <year>1993</year>;<volume>22</volume>(<issue>4</issue>):<fpage>1159</fpage>–<lpage>1167</lpage>.</citation>
</ref>
<ref id="bibr43-1076029611412365">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toschi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lettino</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Tissue factor modulates the thrombogenicity of human atherosclerotic plaques</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>95</volume>(<issue>3</issue>):<fpage>594</fpage>–<lpage>599</lpage>.</citation>
</ref>
<ref id="bibr44-1076029611412365">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matetzky</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kangavari</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Smoking increases tissue factor expression in atherosclerotic plaques: Implications for plaque thrombogenicity</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>102</volume>(<issue>6</issue>):<fpage>602</fpage>–<lpage>604</lpage>.</citation>
</ref>
<ref id="bibr45-1076029611412365">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasterkamp</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schoneveld</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Hijnen</surname>
<given-names>DJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery</article-title>. <source>Atherosclerosis</source>. <year>2000</year>;<volume>150</volume>(<issue>2</issue>):<fpage>245</fpage>–<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr46-1076029611412365">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van den Steen</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Proost</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wuyts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Damme</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Opdenakker</surname>
<given-names>G.</given-names>
</name>
</person-group> <article-title>Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4 and GRO-a and leaves RANTES and MCP-2 intact</article-title>. <source>Blood</source>. <year>2000</year>;<volume>96</volume>(<issue>8</issue>):<fpage>2673</fpage>–<lpage>2681</lpage>.</citation>
</ref>
<ref id="bibr47-1076029611412365">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Falk</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Badimon</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture</article-title>. <source>Circulation</source>. <year>1995</year>;<volume>92</volume>(<issue>6</issue>):<fpage>1565</fpage>–<lpage>1569</lpage>.</citation>
</ref>
<ref id="bibr48-1076029611412365">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>PK.</given-names>
</name>
</person-group> <article-title>Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion</article-title>. <source>Prog Cardiovasc Dis</source>. <year>2002</year>;<volume>44</volume>(<issue>5</issue>):<fpage>357</fpage>–<lpage>368</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>